Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY

Highlights * Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI) * DMX-652 offers potential to address a significant unme...

2026-07-17 14:58 2391

Getinge Interim Report April-June 2026: Good organic growth, high profitability and strong cash flow

GOTHENBURG, Sweden, July 17, 2026 /PRNewswire/ -- "We delivered a strong quarter both financially and operationally with several important key achievements," says Mattias Perjos, President and CEO of Getinge. Sales in Acute Care Therapies increased in most product categories, and the positive ...

2026-07-17 14:45 1957

Creative Life Science Advances PIC/S GMP-Compliant Cell Therapy Materials and Manufacturing Platform

Targets Japan and Singapore as Part of Broader Asia Expansion TAIPEI, July 17, 2026 /PRNewswire/ -- BIO Asia-Taiwan 2026 opens July 16 at the Taipei Nangang Exhibition Center and runs through July 19. Creative Life Science (7837) is showcasing its upstream regenerative medicine materials, proces...

2026-07-17 14:12 1996

Creative Life Science Advances PIC/S GMP-Compliant Cell Therapy Materials and Manufacturing Platform

Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study

* Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. * The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. MELBOURNE, Australia and TOKYO, July 17, 2026 /PRNewswire/ -- Telix...

2026-07-17 06:00 2697

Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing

* First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. * Patient care and research delivered in collaboration with the Melbourne Theranostic Innovation Centre (MTIC), led by its world-class clinical research...

2026-07-16 08:30 3181

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

* First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sydney. * OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA[2] study which recently com...

2026-07-16 04:30 2673

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

MISSISSAUGA, ON, July 15, 2026 /PRNewswire/ -- Septa Pharmaceuticals Inc. , a rapidly growing leader in the Canadian healthcare sector, is proud to announce the succ...

2026-07-15 19:00 1985

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30

- ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibiting greater potency than tirzepatide (EC50 = 3 pM) and is a selective agonist for GIPR without activity for GLP-1R and GCGR. - ASC48 demonstra...

2026-07-15 18:00 2316

Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma

CHENGDU, China, July 15, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced thatthe National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (...

2026-07-15 18:00 2166

Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma

LumaCina Appoints Gary Bird as CEO to Accelerate Growth and Expand Global Sterile Injectables Portfolio

Executive Chair Mark Crotty to continue guiding long-term strategic direction PERTH, Australia, July 15, 2026 /PRNewswire/ -- LumaCina, a global supplier and marketer of steril...

2026-07-15 09:47 3534

LumaCina Appoints Gary Bird as CEO to Accelerate Growth and Expand Global Sterile Injectables Portfolio

Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis

HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9 in the ...

2026-07-15 08:00 2845

Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint

* As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged PFS...

2026-07-15 08:00 2752

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

* Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. * The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical ...

2026-07-13 20:30 1932

Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB

SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-07-13 12:00 2151

AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities

* 873 employees volunteered more than 3,600 hours across 7 Asian markets to support local communities. * Employees partnered with 21 community organizations, positively impacting more than 4,300 people through initiatives focused on patient support, inclusion, education and environmental su...

2026-07-13 10:00 2423

AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo

HANGZHOU, China, SHANGHAI and BOSTON, July 9, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the first patient was successfully dosed on June 30 in...

2026-07-09 08:00 3441

Wegovy® (semaglutide) label updated in Singapore with higher dose supported by STEP UP evidence

* Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks * Mean weight loss with semaglutide 7.2 mg reached 21%, reflecting overall treatment efficacy * Up to 84% of weight loss was driven by reductions in fat mass, supporting meaningful improv...

2026-07-08 09:22 2538

Wegovy® (semaglutide) label updated in Singapore with higher dose supported by STEP UP evidence

Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma

EAST RUTHERFORD, N.J., July 7, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), proudly announces that Snapdragon Chemistry, a Cambrex company, together with NewAmsterdam Pharma, has received the American Chemical Society's 2026 Green Chem...

2026-07-07 20:00 2899

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

SHANGHAI, July 7, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the closing of its previously announc...

2026-07-07 18:53 2868

Ascletis Submits Two IND Applications to U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35

- ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR. - ASC36_35 FDC demonstrated approximately 51% greater relative body weight reducti...

2026-07-06 08:10 3858

12 3 4 5 ... 183

Week's Top Stories

Tetra Pak Introduces Industry-first Carton Packaging for Shelf-stable Tuna to Support Southeast Asia's Growing Tuna Industry

[Picked up by 287 media titles]

2026-07-13 10:00

Tetra Pak Introduces Industry-first Carton Packaging for Shelf-stable Tuna to Support Southeast Asia's Growing Tuna Industry

Klook signs an expanded two-year partnership with Korea Tourism Organization

[Picked up by 286 media titles]

2026-07-16 17:49